We have shown that treatment with EGF up-regulates SPRY2 expression, and overexpression of SPRY2 attenuates EGF-induced E-cadherin down-regulation and cell invasion in human ovarian cancer cells [25]. The gene discussed is CDH1; the disease is ovarian carcinoma.